Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

Author:

Bennett Chijioke,Woo Wayne,Bloch Mark,Cheung King,Griffin Paul,Mohan Rahul,Deshmukh Sachin,Arya Mark,Cumming Oscar,Neville A Munro,McCallum Pardey Toni G,Plested Joyce S,Cloney-Clark Shane,Zhu Mingzhu,Kalkeri Raj,Patel Nita,Marcheschi Alex,Swan Jennifer,Smith Gale,Cho Iksung,Glenn Gregory M,Walker Robert,Mallory Raburn M,Anderson Anna,Ang Mary,Barnes Timothy,Bassin Michelle,Bessey Kate,Bowler Simon,Bull Sheetal,Burr Lucy,Burton Robert,Byrne Michelle,Carroll Robert,Chee Nicholas,Choy Aaron,Clark Malcolm,Dalebout Marije,De Wet Peter,Deshmukh Kshama,Diez Alvarez Sergio,Douglas Dominic,Engelander Jacqueline,Evangelista Carla,Game Stuart,Glass Noor,Gunner Elizabeth,Han Jennifer,Harrison Michael,Hing Kiang Jason Doong,Hlaing Thazin,Joshi Divyansh,Joyce Sheree,Kaluhin Karen,Kavic Milanka,Kononov Juliana,Lee Gary,Lee Wei-I,Leelasena Indika,Leong Esmond,Lim Ivan,Lister Graham,Loh Denissa,Magdy Mary,Maggs Callum,Mammoottil Amith,McCarthy Shannon,McKay Nicole,Melek Mariah,Michael Barnett Adrian,Mohan Rahul,Moore Andrew,Moore Amanda,Murdoch Louise,Napier-Flood Fiona,Narsai Ushma,Neville Alexander,Nguyen Paul,Odarchenko Ekaterina,Pardey Toni,Quan Dick,Ranagsinghe Ushank,Rasalam Roy,Rayar Shiva,Ruthnam Gonasagaran Jay,Seet Pi,Smith Deon,Srilakshmanan Krishna,Taggart Angela,Tiong Florence,Toh Boon,Ujvary Eniko,Wallace Stephanie,Wolf Rebecca,Wong Ian,Yoo Hye,Young Rhys

Funder

Novavax Inc

Publisher

Elsevier BV

Reference28 articles.

1. Neutralization of omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine;Kurhade;Nat Commun,2022

2. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5;Tartof;Lancet Infect Dis,2022

3. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5;Tseng;Nat Commun,2023

4. The rapid rise of SARS-CoV-2 omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants;Ao;MedComm (2020),2023

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3